$CWBR News

Last published 3y ago

3y agoCWBRCohBar Reports Second Quarter 2023 Financial ResultsGlobeNewswireMENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and
3y agoCWBR EMAN GHL KDNYMoore Kuehn Encourages CWBR, KDNY, GHL, and EMAN Investors to Contact Law FirmGlobeNewswireNEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoCWBR DM GHL KDNYMoore Kuehn Encourages CWBR, KDNY, GHL, and DM Investors to Contact Law FirmPR NewswireNEW YORK, July 17, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
3y agoCWBRMorphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)GlobeNewswireIFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with anIFx-Hu2.0 demonstrated to have a promising safety profile at
3y agoCWBRMorphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireTAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines
3y agoCWBRMorphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingACCESS NewswireTAMPA, FL / ACCESSWIRE / May 30, 2023 / Morphogenesis, Inc. , a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor
3y agoCWBRCohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer ImmunotherapyGlobeNewswireCombined company will operate under the name "TuHURA Biosciences, Inc." and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase
4y agoCWBRCohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewswireMENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop
4y agoCWBRCohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022GlobeNewswireMENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop
4y agoCWBRCohBar Announces Reverse Stock SplitGlobeNewswireMENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics tar
4y agoCWBRCohBar to Present at H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireMENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics tar
4y agoCWBRCohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewswireIND for CB5138-3 on track for second half of 2023 Conference call and webcast today at 5:00 p.m. ET, August 15, 2022 MENLO PARK, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveragi
4y agoCWBRCohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022GlobeNewswireMENLO PARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targ
4y agoCWBRCohBar Appoints Effie Tozzo, Ph.D. to Its Board of DirectorsGlobeNewswireMENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targ
4y agoCWBRCohBar to Participate at Upcoming Conferences in June 2022GlobeNewswireMENLO PARK, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targ
4y agoCWBRCohBar to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireMENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targe
4y agoCWBRCohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate ProgressGlobeNewswireMENLO PARK, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targe
4y agoCWBRCohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting ProposalGlobeNewswireMENLO PARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) (the "Company"), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough th
4y agoCWBRCohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022GlobeNewswireMENLO PARK, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targe
4y agoCWBRCohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireMENLO PARK, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics tar
4y agoCWBRCohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022GlobeNewswireMENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics tar
4y agoCWBRCohBar to Present at H.C. Wainwright BIOCONNECT ConferenceGlobeNewswireMENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targ
4y agoACST AVCT CWBR QNRX+1Thinking about buying stock in SeaChange International, American Virtual Cloud Technologies, Quoin Pharmaceuticals, Acasti Pharma, or CohBar?PR NewswireNEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEAC, AVCT, QNRX, ACST, and CWBR.
4y agoCWBRCohBar Announces Changes to its Board of Directors and R&D LeadershipGlobeNewswireFounding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage
4y agoCWBRCohBar's CEO to Participate in Upcoming BIO WebinarGlobeNewswireMENLO PARK, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced its Chief Executi
4y agoCWBRCohBar Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireCompany to host conference call at 5:00 p.m. ET MENLO PARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten
5y agoCWBRCohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021GlobeNewswireMENLO PARK, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company
5y agoCWBRCohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and WarrantsGlobeNewswireMENLO PARK, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) (the "Company"), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced t
5y agoCWBRCohBar Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewswireMENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) (the "Company"), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced a
5y agoCWBRCohBar to Present at H.C. Wainwright 5th Annual NASH Investor ConferenceGlobeNewswireMENLO PARK, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Ex
5y agoCWBR GOGL INDI RWLK+1Thinking about buying stock in Rewalk Robotics, Viridian Therapeutics, CohBar, Golden Ocean Group, or Indie Semiconductor?PR NewswireNEW YORK, Sept. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RWLK, VRDN, CWBR, GOGL, and INDI.
5y agoCWBRCohBar Appoints Joanne Yun, Ph.D. to Its Board of DirectorsGlobeNewswireMENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment
5y agoCWBRCohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)GlobeNewswireMENLO PARK, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the United State
5y agoCWBRCohBar to Present at Upcoming Investor ConferencesGlobeNewswireMENLO PARK, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief E
5y agoAMRS BKE CWBR QFIN+1Thinking about buying stock in 360 DigiTech, CohBar, Buckle, Amyris, or Senseonics?PR NewswireNEW YORK, Aug. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QFIN, CWBR, BKE, AMRS, and SENS. T
5y agoCWBRCohBar Appoints Carol Nast to Its Board of DirectorsGlobeNewswireMENLO PARK, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment o
5y agoATHX CELU CWBR GERN+1How Aging-Related Conditions Are Increasing The Treatment Burden For Older PatientsPR NewswirePALM BEACH, Fl., Aug. 13, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The normal aging process is characterized by a progression of physiologic events that occur throughout the life cycle. Changes associated with aging occur throughout
5y agoCWBR MU NAOV OCX+1Thinking about buying stock in Micron, NanoVibronix, OncoCyte, PG&E Corp, or CohBar?PR NewswireNEW YORK, Aug. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MU, NAOV, OCX, PCG, and CWBR. To s
5y agoBCRX CWBR HOTH MOGO+1Thinking about buying stock in CohBar, Mogo, BioCryst Pharmaceuticals, Hoth Therapeutics, or Maravai Lifesciences?PR NewswireNEW YORK, Aug. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CWBR, MOGO, BCRX, HOTH, and MRVI. T
5y agoCWBRCohBar Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireMENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial resu
5y agoCWBRCohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021GlobeNewswireMENLO PARK, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company
5y agoCWBRCohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and ObesityGlobeNewswireMENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced an update on the
5y agoCLRB CWBR DARE INDI+1Thinking about buying stock in indie Semiconductor, CohBar, Cellectar Biosciences, Lucira Health, or Dare Bioscience?PR NewswireNEW YORK, July 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INDI, CWBR, CLRB, LHDX, and DARE. T
5y agoCWBRCohBar to Present at the BIO 2021 Digital ConferenceGlobeNewswireMENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced its Chief Executi
5y agoCWBRCohBar Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireMENLO PARK, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial resul
5y agoCWBRCohBar, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 17, 2021 / CohBar, Inc. (NASDAQ:CWBR) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 17, 2021 at 5:00 PM Eastern Time. To listen to the event live or access a replay
5y agoCWBRCohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021GlobeNewswireMENLO PARK, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company
5y agoCWBRCohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and DirectorGlobeNewswireMENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment
5y agoCWBRCohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and ObesityGlobeNewswireMENLO PARK, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that the last su
5y agoCWBRCohBar to Present at the Mitochondria-Targeted Drug Development SummitGlobeNewswireMENLO PARK, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...